文献速递淋巴瘤造血干细胞移植与细胞治疗

侵袭性B细胞淋巴瘤CAR-T治疗后患者报告症状性不良事件与医生评估的一致性:前瞻性研究

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.
PubMed 文献 · Lancet Haematol · 2026-06-12

该前瞻性多中心研究纳入170例接受CAR-T治疗的侵袭性B细胞淋巴瘤患者,于输注后第10天采用PRO-CTCAE评估患者报告的症状性不良事件,并与医生CTCAE评估对比。结果显示12/19种症状发生率超50%,中重度疲劳、食欲下降等常见,医生对胃肠道症状普遍低估。

要点

  • CAR-T后第10天患者报告疲劳(87%)、食欲下降(83%)等12种症状发生率超50%。
  • 中重度疲劳(55%)、食欲下降(53%)、腹泻(45%)等负担较重。
  • 医生对吞咽困难、食欲下降、恶心、腹泻等胃肠道症状普遍低估。

核心结论

  • CAR-T治疗后早期患者报告症状负担高,医生评估常低估症状,尤其胃肠道症状。

研究设计与样本

  • 前瞻性、观察性、多中心研究,意大利13个中心,纳入170例接受CAR-T治疗的侵袭性B细胞淋巴瘤患者。

主要发现

  • 165例达到第10天时间点,其中143例(87%)完成PRO-CTCAE量表。
  • 19种症状中12种任何等级发生率超过50%:疲劳87%(123/141)、食欲下降83%(116/139)、失眠79%(112/142)等。
  • 中重度症状发生率:疲劳55%(78/141)、食欲下降53%(74/139)、腹泻45%(63/141)、寒战35%(49/142)、失眠31%(44/142)。
  • 医生低估胃肠道症状:吞咽困难78%(28/36)、食欲下降77%(75/98)、恶心70%(43/61)、腹泻71%(60/85)。

临床怎么用

  • 临床应更系统使用患者报告结局量表,以补充医生评估的不足,及时识别支持治疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise in treating patients with haematological malignancies. We aimed to investigate short-term patient-reported symptomatic adverse events in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy and compare them with those reported by their treating physicians. We also examined factors predicting overall short-term burden of therapy. METHODS: This was a prospective, observational, multicentre study enrolling patients across 13 centres in Italy. Eligible patients were aged 18 years and older with a confirmed diagnosis of aggressive B-cell lymphoma. All patients were scheduled to undergo CAR T-cell therapy with one of the following products: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or brexucabtagene autoleucel (brexu-cel). The primary objective of this analysis was to assess the prevalence of short-term patient-reported symptomatic adverse events overall and by sex and age categories. The primary objective was evaluated on day 10 after infusion via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), which includes 19 items selected based on their clinical relevance, including: difficulty swallowing, decreased appetite, nausea, diarrhoea, swelling, hair loss, dizziness, concentration difficulty, memory difficulty, general pain, headache, muscle pain, joint pain, insomnia, fatigue, anxiety, discouragement, sadness, and chills. Prevalence of symptomatic adverse events was also assessed by type of CAR T-cell product. Additionally, the study was designed to allow a corresponding adverse event assessment via the CTCAE by treating haematologists for comparative analysis. Adverse events reported by physicians were matched with corresponding adverse events reported by patients. Furthermore, an overall symptom burden score was computed and used as outcome variable in multivariable analysis to examine factors predicting short-term burden of therapy, including sociodemographic and clinical data and pre-infusion patient-reported physical functioning by the EORTC QLQ-C30. The study is registered with ClinicalTrials.gov, NCT06026644, and is closed to accrual and follow-up is complete. FINDINGS: Between June 29, 2022, and Feb 26, 2024, 170 patients were included in the study. The median age of patients was 61·1 years (IQR 51·1-68·5) and the median follow-up was 23·7 months (17·7-24·6). 53 (31%) of 170 enrolled patients were female and 117 (69%) were male. Most patients were diagnosed with diffuse large B-cell lymphoma (118 [69%] patients), followed by mantle cell lymphoma (32 [19%] patients) and primary mediastinal large B-cell lymphoma (20 [12%] patients). 98 (58%) patients were infused with axi-cel, 39 (23%) with tisa-cel, and 32 (19%) with brexu-cel. 165 patients reached the day 10 timepoint, of whom 143 (87%) completed the corresponding PRO-CTCAE item list. We observed a prevalence (any grade) of more than 50% across 12 of the 19 symptomatic adverse events examined: fatigue (123 [87%] of 141 patients), decreased appetite (116 [83%] of 139 patients), insomnia (112 [79%] of 142 patients), chills (103 [73%] of 142 patients), diarrhoea (99 [70%] of 141 patients), sadness (81 [57%] of 141 patients), general pain (78 [55%] of 143 patients), dizziness (78 [55%] of 143 patients), joint pain (74 [52%] of 142 patients), muscle pain (73 [51%] of 143 patients), headache (73 [51%] of 143 patients), and impaired concentration (72 [51%] of 142 patients). Inspection of moderate to severe grades revealed that more than 30% of patients reported fatigue (78 [55%] of 141 patients), decreased appetite (74 [53%] of 139 patients), diarrhoea (63 [45%] of 141 patients), chills (49 [35%] of 142 patients), and insomnia (44 [31%] of 142 patients). Physicians frequently under-reported symptoms in their patients. For example, gastrointestinal symptoms were consistently under-reported, including difficulty swallowing (28 [78%] of 36 patients), decreased appetite (75 [77%] of 98 participants), nausea (43 [70%] of 61 participants), and diarrhoea (60 [71%] of 85 participants). INTERPRETATION: Our findings could assist clinicians in delivering more targeted and timely supportive care interventions and might inform patients about anticipated symptoms during the early post-CAR T-cell infusion period. Moreover, the observed discrepancies between patient-reported and clinician-reported symptoms suggest that more systematic use of patient-reported outcome measures might provide complementary insights beyond those captured through clinician assessment. FUNDING: Fondazione GIMEMA Franco Mandelli Onlus and Novartis Farma Italy.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Efficace F, Zinzani PL, Bonifazi F, et al. Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study. Lancet Haematol. 2026. PMID: 42285114. doi:10.1016/S2352-3026(26)00128-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。